Cargando…

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy

BACKGROUND: The tumor-selective human adenovirus Delta24-RGD is currently under investigation in phase II clinical trials for patients with recurrent glioblastoma (GBM). To improve treatments for patients with GBM, we explored the potential of combining Delta24-RGD with antibodies targeting immune c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belcaid, Zineb, Berrevoets, Cor, Choi, John, van Beelen, Edward, Stavrakaki, Eftychia, Pierson, Tessa, Kloezeman, Jenneke, Routkevitch, Denis, van der Kaaij, Mariëlle, van der Ploeg, Alicia, Mathios, Dimitrios, Sleijfer, Stefan, Dirven, Clemens, Lim, Michael, Debets, Reno, Lamfers, Martine L M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212906/ https://www.ncbi.nlm.nih.gov/pubmed/32642679 http://dx.doi.org/10.1093/noajnl/vdaa011

Ejemplares similares

The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity
por: Kleijn, Anne, et al.
Publicado: (2014)

Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
por: Balvers, Rutger K., et al.
Publicado: (2014)

Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
por: Stavrakaki, Eftychia, et al.
Publicado: (2021)

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity
por: Kleijn, Anne, et al.
Publicado: (2017)

A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells
por: Kleijn, A., et al.
Publicado: (2016)

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

THER-02. Pediatric brain tumor cultures reveal differential susceptibility to four oncolytic viruses
por: Vazaios, Konstantinos, et al.
Publicado: (2022)

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
por: Balvers, Rutger K, et al.
Publicado: (2015)

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
por: van Putten, Erik H.P., et al.
Publicado: (2022)

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2
por: Venkatesan, Subramanian, et al.
Publicado: (2016)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients
por: Klaver, Yarne, et al.
Publicado: (2016)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
por: Kunert, Andre, et al.
Publicado: (2013)

Curdlan, zymosan and a yeast-derived β-glucan reshape tumor-associated macrophages into producers of inflammatory chemo-attractants
por: de Graaff, Priscilla, et al.
Publicado: (2020)

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

The Multifaceted Role of Macrophages in Oncolytic Virotherapy
por: Hofman, Laura, et al.
Publicado: (2021)

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
por: Bins, Sander, et al.
Publicado: (2018)

Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates
por: Bots, Selas T.F., et al.
Publicado: (2022)

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
por: Straetemans, Trudy, et al.
Publicado: (2012)

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
por: Schirrmacher, Volker, et al.
Publicado: (2019)

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Oncolytic Viral Therapy for Mesothelioma
por: Pease, Daniel F., et al.
Publicado: (2017)

Oncolytic viruses in cancer therapy
por: Vähä-Koskela, Markus J.V., et al.
Publicado: (2007)

Oncolytic Adenoviruses for Cancer Therapy
por: Tripodi, Lorella, et al.
Publicado: (2021)

Concepts in Oncolytic Adenovirus Therapy
por: Mantwill, Klaus, et al.
Publicado: (2021)

A prospective, randomized placebo‐controlled clinical trial on the effects of a fluoride rinse on white spot lesion development and bleeding in orthodontic patients
por: van der Kaaij, Nicoline C. W., et al.
Publicado: (2015)

T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression
por: Mustafa, Dana A. M., et al.
Publicado: (2018)

Molecular imaging of oncolytic viral therapy
por: Haddad, Dana, et al.
Publicado: (2015)

Oncolytic Viruses for Multiple Myeloma Therapy
por: Calton, Christine M., et al.
Publicado: (2018)

Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases
por: Vorobyev, P. O., et al.
Publicado: (2022)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

CD45RA(+)CCR7(−) CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
por: Kunert, Andre, et al.
Publicado: (2019)

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
por: Abudoureyimu, Mubalake, et al.
Publicado: (2019)

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma
por: Choi, John, et al.
Publicado: (2021)

Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
por: Abudoureyimu, Mubalake, et al.
Publicado: (2020)

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
por: Siddiqui, Imran, et al.
Publicado: (2016)

Antibody formation to enzyme therapy in classic infantile Pompe disease: implications of patient age
por: van Gelder, C, et al.
Publicado: (2013)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles
por: Wong, Han Hsi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_avs0c466v9vqv9in04uvjk6cds